A corporate venture capital arm of a global pharmaceutical company invests in innovative digital health companies worldwide. Established in 2015, the firm supports companies from Seed through later-stage venture financings and can invest up to approximately $5M per financing round. The firm seeks strategic investments that complement its parent company’s long-term healthcare priorities while helping portfolio companies accelerate product development and commercial adoption.
The firm focuses exclusively on digital health, with particular interest in prevention and medication adherence technologies, digital therapeutics, digital medical devices, and big data analytics platforms. Key areas of interest include chronic diseases such as diabetes, obesity, and cardiovascular disease, as well as respiratory diseases, oncology, consumer health, and mental health. The firm seeks innovative technologies that improve patient outcomes through connected care, data-driven insights, and digital healthcare solutions.
From a company and management team perspective, the firm prefers experienced leadership teams with demonstrated expertise in their respective markets and well-developed business plans. The firm partners with companies globally and seeks management teams capable of successfully commercializing innovative digital health technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 